182 related articles for article (PubMed ID: 37289410)
1. Natamycin Ocular Delivery: Challenges and Advancements in Ocular Therapeutics.
Mascarenhas M; Chaudhari P; Lewis SA
Adv Ther; 2023 Aug; 40(8):3332-3359. PubMed ID: 37289410
[TBL] [Abstract][Full Text] [Related]
2. Natamycin solid lipid nanoparticles - sustained ocular delivery system of higher corneal penetration against deep fungal keratitis: preparation and optimization.
Khames A; Khaleel MA; El-Badawy MF; El-Nezhawy AOH
Int J Nanomedicine; 2019; 14():2515-2531. PubMed ID: 31040672
[TBL] [Abstract][Full Text] [Related]
3. The preparation and therapeutic effects of β-glucan-specific nanobodies and nanobody-natamycin conjugates in fungal keratitis.
Liu X; Sui J; Li C; Wang Q; Peng X; Meng F; Xu Q; Jiang N; Zhao G; Lin J
Acta Biomater; 2023 Oct; 169():398-409. PubMed ID: 37579912
[TBL] [Abstract][Full Text] [Related]
4. Nanomicelles empower natamycin in treating fungal keratitis: An in vitro, ex vivo and in vivo study.
Sathe P; Kailasam V; Nagarjuna V; Sharma H; Velpandian T; Garg P; Nirmal J
Int J Pharm; 2024 May; 656():124118. PubMed ID: 38615806
[TBL] [Abstract][Full Text] [Related]
5. Natamycin niosomes as a promising ocular nanosized delivery system with ketorolac tromethamine for dual effects for treatment of candida rabbit keratitis; in vitro/in vivo and histopathological studies.
El-Nabarawi MA; Abd El Rehem RT; Teaima M; Abary M; El-Mofty HM; Khafagy MM; Lotfy NM; Salah M
Drug Dev Ind Pharm; 2019 Jun; 45(6):922-936. PubMed ID: 30744431
[TBL] [Abstract][Full Text] [Related]
6. Fungal keratitis caused by Scopulariopsis brevicaulis treated successfully with natamycin.
Malecha MA
Cornea; 2004 Mar; 23(2):201-3. PubMed ID: 15075891
[TBL] [Abstract][Full Text] [Related]
7. Thermosensitive Tri-Block Polymer Nanoparticle-Hydrogel Composites as Payloads of Natamycin for Antifungal Therapy Against
Sha X; Chan L; Fan X; Guo P; Chen T; Liu L; Zhong J
Int J Nanomedicine; 2022; 17():1463-1478. PubMed ID: 35378880
[TBL] [Abstract][Full Text] [Related]
8. Enhanced in vivo antifungal activity of novel cell penetrating peptide natamycin conjugate for efficient fungal keratitis management.
Rohira H; Shankar S; Yadav S; Shah SG; Chugh A
Int J Pharm; 2021 May; 600():120484. PubMed ID: 33737097
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic response time of topical voriconazole 1% and intrastromal voriconazole 0.05% versus topical natamycin 5% monotherapy in Fusarium keratitis in rabbit.
Edwar L; Janna YM; Rozaliyani A; Louisa M
Mycoses; 2020 Oct; 63(10):1128-1132. PubMed ID: 32780874
[TBL] [Abstract][Full Text] [Related]
10. Comparison of topical itraconazole 1% with topical natamycin 5% for the treatment of filamentous fungal keratitis.
Kalavathy CM; Parmar P; Kaliamurthy J; Philip VR; Ramalingam MD; Jesudasan CA; Thomas PA
Cornea; 2005 May; 24(4):449-52. PubMed ID: 15829804
[TBL] [Abstract][Full Text] [Related]
11. Secondary pseudomonas infection of fungal keratitis following use of contaminated natamycin eye drops: a case series.
Krishnan T; Sengupta S; Reddy PR; Ravindran RD
Eye (Lond); 2009 Feb; 23(2):477-9. PubMed ID: 18820656
[TBL] [Abstract][Full Text] [Related]
12. Improved Topical Ophthalmic Natamycin Suspension for the Treatment of Fungal Keratitis.
Cai C; Youssef AAA; Joshi PH; Varner C; Dudhipala N; Majumdar S
J Ocul Pharmacol Ther; 2024; 40(1):67-77. PubMed ID: 38117668
[No Abstract] [Full Text] [Related]
13. Pharmacologic therapy of mycotic keratitis.
Sahay P; Singhal D; Nagpal R; Maharana PK; Farid M; Gelman R; Sinha R; Agarwal T; Titiyal JS; Sharma N
Surv Ophthalmol; 2019; 64(3):380-400. PubMed ID: 30797882
[TBL] [Abstract][Full Text] [Related]
14. Corneal targeted nanoparticles for sustained natamycin delivery and their PK/PD indices: an approach to reduce dose and dosing frequency.
Chandasana H; Prasad YD; Chhonker YS; Chaitanya TK; Mishra NN; Mitra K; Shukla PK; Bhatta RS
Int J Pharm; 2014 Dec; 477(1-2):317-25. PubMed ID: 25455776
[TBL] [Abstract][Full Text] [Related]
15. Cell penetrating peptides as efficient nanocarriers for delivery of antifungal compound, natamycin for the treatment of fungal keratitis.
Jain A; Shah SG; Chugh A
Pharm Res; 2015 Jun; 32(6):1920-30. PubMed ID: 25467959
[TBL] [Abstract][Full Text] [Related]
16. Novel water soluble sterile natamycin formulation (Natasol) for fungal keratitis.
Velpandian T; Nirmal J; Sharma HP; Sharma S; Sharma N; Halder N
Eur J Pharm Sci; 2021 Aug; 163():105857. PubMed ID: 33882328
[TBL] [Abstract][Full Text] [Related]
17. Fungal keratitis: A review of clinical presentations, treatment strategies and outcomes.
Sharma N; Bagga B; Singhal D; Nagpal R; Kate A; Saluja G; Maharana PK
Ocul Surf; 2022 Apr; 24():22-30. PubMed ID: 34915188
[TBL] [Abstract][Full Text] [Related]
18. The clinical and microbiological features and outcomes of fungal keratitis over 9 years in Sydney, Australia.
Watson SL; Cabrera-Aguas M; Keay L; Khoo P; McCall D; Lahra MM
Mycoses; 2020 Jan; 63(1):43-51. PubMed ID: 31556179
[TBL] [Abstract][Full Text] [Related]
19. Mesoporous zinc oxide-based drug delivery system offers an antifungal and immunoregulatory strategy for treating keratitis.
Gu L; Lin J; Wang Q; Meng F; Niu G; Lin H; Chi M; Feng Z; Zheng H; Li D; Zhao G; Li C
J Control Release; 2024 Apr; 368():483-497. PubMed ID: 38458571
[TBL] [Abstract][Full Text] [Related]
20. Fungal Keratitis: Epidemiology, Rapid Detection, and Antifungal Susceptibilities of
Manikandan P; Abdel-Hadi A; Randhir Babu Singh Y; Revathi R; Anita R; Banawas S; Bin Dukhyil AA; Alshehri B; Shobana CS; Panneer Selvam K; Narendran V
Biomed Res Int; 2019; 2019():6395840. PubMed ID: 30800674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
